Physician profile
Jeffrey Kahn
NPI 1639194822
$8,755.84
in general payments reported to CMS, 2019-2025
13 companies · $1,184 in 2025
The $1,184 reported for 2025 was more than what a typical Transplant Hepatology provider received nationally (typical 2025 total: $508).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $674 · 2020: $119 · 2021: $741 · 2022: $2,500 · 2023: $3,234 · 2024: $303 · 2025: $1,184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $2,700 · Food and Beverage: $1,621 · Consulting Fee: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $2,700.00 |
| Food and Beverage | $1,621.11 |
| Consulting Fee | $400.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orphalan INC | $2,916.32 | 2023-2025 | Cuvrior |
| Mallinckrodt Hospital Products INC. | $1,860.00 | 2022 | |
| Abbvie INC. | $1,150.52 | 2019-2025 | |
| Gilead Sciences, INC. | $780.91 | 2019-2025 | Livdelzi |
| Intercept Pharmaceuticals, INC. | $741.43 | 2021-2023 | Ocaliva |
| Madrigal Pharmaceuticals | $433.20 | 2024-2025 | Rezdiffra |
| Glaxosmithkline, LLC. | $400.00 | 2025 | |
| Dova Pharmaceuticals | $215.34 | 2020-2021 | |
| Boston Scientific Corporation | $169.60 | 2025 | Therasphere Administration Set |
| Ipsen Biopharmaceuticals, INC | $37.87 | 2025 | Iqirvo |
| Mirum Pharmaceuticals, INC. | $19.25 | 2025 | Livmarli |
| Itamar Medical INC | $18.36 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Kahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.